Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Schneider, Robert; Babb, J; Bishop, H.; Mitchard, M.; Hoare, A M

doi:10.1136/bmj.2.6039.794

Cited by 47 publications

(34 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher than normal plasma propranolol concentrations have been reported in coeliac disease (Parsons et al, 1976;Schneider et al, 1976), Crohn's disease and rheumatoid arthritis (Schneider et al, 1979). Explanations which have been offered include increased absorption of the drug, improved bioavailability due to a reduction in 'first-pass' metabolism across the liver, or a change in the distribution volume of the drug.…”

Section: Intravenous Propranolol In Patients With Inflammationmentioning

confidence: 99%

Intravenous propranolol in patients with inflammation.

Waller¹,

Smith²,

Renwick³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Intravenous Propranolol In Patients With Inflammationmentioning

confidence: 99%

Intravenous propranolol in patients with inflammation.

Waller¹,

Smith²,

Renwick³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Marked variations in serum levels of a number of therapeutic agents have been dem onstrated in patients with both Crohn's dis ease and coeliac disease (1)(2)(3)(4). This has been documented in subjects with demonstrable malabsorption (3) and also in subjects whose mucosa and absorptive function appeared normal (1,2).…”

mentioning

confidence: 99%

“…The mechanism of action of prednisolone is controversial (7), but a sys temic rather than a topical effect seems likely. In Crohn's disease there is evidence for a widespread mucosal abnormality (8) and pre vious studies have shown changes in drug serum levels even in the absence of 'typical' Crohn's involvement of the upper small bowel (4).…”

mentioning

confidence: 99%

Serum Prednisolone Levels in Crohn’s Disease and Coeliac Disease following Oral Prednisolone Administration

Tanner

Halliday

Powell³

1981

Digestion

View full text Add to dashboard Cite

Serum prednisolone levels have been measured following the oral administration of 20 mg prednisolone in 10 normal subjects, in 9 patients with Crohn’s disease and in 6 with coeliac disease. Serum prednisolone levels showed more variation in patients with Crohn’s disease when compared to normal subjects. In those patients with Crohn’s disease who failed to respond to corticosteroid therapy, adequate serum levels of prednisolone were achieved. Patients with coeliac disease had levels similar to normal. Serum protein binding of prednisolone was not significantly different between the groups. We conclude that, even in the presence of mucosal damage, patients with coeliac disease and Crohn’s disease achieve therapeutic serum prednisolone levels.

show abstract

“…The effect of increased binding on the pharmacokinetics of these drugs has been evaluated in several studies. After oral administration the serum concentrations of propranolol and oxprenolol are higher when inflammation is present, in man (Schneider et al, 1976;Kendall et al, 1979) as well as in animals (Belpaire et al, 1981;Bishop et al, 1981;Barber et al, 1983). After intravenous administration, there is still a difference between serum concentrations of the P-adrenoceptor blockers in healthy and diseased individuals, in man (De Leve & Piafsky, 1981;Waller et al, 1982) and experimental animals (Belpaire et al, 1981;Bishop et al, 1981;Barber et al, 1983), but it is less pronounced.…”

Section: Introductionmentioning

confidence: 99%

Binding to serum α₁‐acid glycoprotein and effect of β‐adrenoceptor antagonists in rats with inflammation

Belpaire

Bogaert

Mugabo

et al. 1986

British J Pharmacology

View full text Add to dashboard Cite

1 The P-blocking effect of 4 P-adrenoceptor antagonists with different pharmacokinetic properties was studied after intravenous and intraportal administration to control rats and to rats with experimental inflammation. 2 In rats with inflammation the effects of propranolol and oxprenolol, which are mainly bound to a,-acid glycoprotein (ax-AGP), were significantly less after intravenous administration, but not after intraportal administration. In contrast, for metoprolol and atenolol, which are only negligibly serum bound, no difference was observed between control rats and rats with inflammation for either route of administration. 3 Total and unbound serum concentrations of propranolol were measured 20 min after intravenous and intraportal administration. 4 After intravenous administration, in the rats with inflammation total concentrations of propranolol were more than twice, and unbound concentrations less than half those of control rats. After intraportal administration the total concentrations were 8 times, and the unbound concentrations 3 times higher in the rats with inflammation. 5There was a significant correlation between the P-blocking effect and the unbound concentrations of propranolol after intravenous administration, but not after intraportal administration. The latter finding is probably because the unbound concentrations were supramaximal.

show abstract

Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Cited by 47 publications

References 2 publications

Intravenous propranolol in patients with inflammation.

Intravenous propranolol in patients with inflammation.

Serum Prednisolone Levels in Crohn’s Disease and Coeliac Disease following Oral Prednisolone Administration

Binding to serum α₁‐acid glycoprotein and effect of β‐adrenoceptor antagonists in rats with inflammation

Contact Info

Product

Resources

About

Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Cited by 47 publications

References 2 publications

Intravenous propranolol in patients with inflammation.

Intravenous propranolol in patients with inflammation.

Serum Prednisolone Levels in Crohn’s Disease and Coeliac Disease following Oral Prednisolone Administration

Binding to serum α1‐acid glycoprotein and effect of β‐adrenoceptor antagonists in rats with inflammation

Contact Info

Product

Resources

About

Binding to serum α₁‐acid glycoprotein and effect of β‐adrenoceptor antagonists in rats with inflammation